Biotech investment firm TCGX said Wednesday it closed TCGX Asia Life Sciences Fund I, an oversubscribed $600 million vehicle backed by a diverse group of international institutional investors that will focus on innovative biotechnology companies based in Asia, investing across stages of company development. The fund will operate separately from, but in close synergy with, TCGX’s Flagship Funds, which back biotechs in the U.S. and Europe. In connection with the launch, TCGX is expanding to Asia with new offices in Shanghai and Hong Kong; Dandan Dong, previously chief business officer at ArriVent Biopharma, will oversee the region as managing partner of TCGX Asia.
Asia has become an increasingly important source of globally competitive biotechnology innovation, founder and managing partner Chen Yu said, pointing to the explosive growth of early-stage drug discovery in China. The California-based investor has raised $3.1 billion across its vehicles since its first $824 million fund in 2021, backing Western biotechs through buyouts and IPOs.
The raise formalizes what this week’s deal flow already showed: Asia is no longer just a sourcing market for Western pharma but a destination for dedicated capital. Roche’s reported $1 billion discovery partnership with China’s Defand Therapeutics, Bambusa Therapeutics’ IPO filing on assets licensed from BioNTech’s Chinese subsidiary, and a steady stream of cross-border licenses have made the region a standalone investment thesis.